Experimental stomach cancer combo trial halted after only 2 patients

NCT ID NCT07040059

First seen Apr 28, 2026 · Last updated May 13, 2026 · Updated 2 times

Summary

This early-stage study tested a new drug called AUR103 combined with standard treatments (trastuzumab and chemotherapy) for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal was to see if the combination was safe and effective. However, the study was terminated early and only enrolled 2 participants, so no conclusions can be drawn.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asha Hospital and Research Centre

    Bangalore, Karnataka, 560076, India

  • HCG Cancer Center

    Vizag, Andhra Pradesh, 530040, India

  • Hope & Heal Cancer Hospital and Research Center

    Siliguri, West Bengal, 734015, India

  • Karnataka Cancer Hospital and Radiation Theraphy Center

    Bangalore, Karnataka, 560096, India

  • Kiran Hospital Multi Super Speciality Hospital & Reseach Center

    Surat, Gujarat, 395004, India

  • Netaji Subhas Chandra Bose Cancer Hospital

    Kolkata, West Bengal, 700094, India

  • Shalby Hospital

    Ahmedabad, Gujarat, 380015, India

  • The Gujarat Cancer & Research Insititute

    Ahmedabad, Gujarat, 380016, India

Conditions

Explore the condition pages connected to this study.